NOV 2 4 2003

Flease type a plus sign (+) inside this box —

Under the Paperwork Reduction Act valid OMB control number

type a plus sign (+) inside this box \longrightarrow + Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | Application Number | 10/647,358 | | | |
|--|------------------------|----------------------|--|--|--|
| TRANSMITTAL | Filing Date | August 25, 2003 | | | |
| FORM | First Named Inventor | Bisgaier, Charles L. | | | |
| (to be used for all correspondence after initial filing) | Group Art Unit | 1617 | | | |
| | Examiner Name | Unknown | | | |
| Total Number of Pages in This Submission | Attorney Docket Number | 5790-C1-HMB | | | |

| Total Number of | i Pages III Tilis Subilii | 331011 | | Attorney Docket Numb | C1 | |
|------------------------------|--|---------|------------------------------|---|---|---|
| | | | ENCLOS | URES (check all that a | oply) | |
| Fee Transm | ittal Form | | | nent Papers | | After Allowance Communication to Group |
| Fee A | uttached · | | Drawing | (s) | | Appeal Communication to Board of Appeals and Interferences |
| Amendmen | t / Response | | Licensin | g-related Papers | | Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| Afte | r Final | | Petition and Acc | Routing Slip (PTO/SB/69) ompanying Petition | | Proprietary Information |
| Affid | lavits/declaration(s) | | | to Convert to a nal Application | | Status Letter |
| Extension of Time Request | | | Power o Change Address | f Attorney, Revocation of Correspondence | | Additional Enclosure(s) (please identify below): |
| Express Ab | | Termina | l Disclaimer | | All Cited References Return Postcard | |
| | | Small E | ntity Statement | | | |
| Information | | Reques | t for Refund | | | |
| | Certified Copy of Priority Document(s) | | arks | | | |
| | to Missing Parts/ Application | | | • | | |
| | ponse to Missing | | | | | |
| | s under 37 CFR or 1.53 | | | | | |
| | SIGNATU | RE O | F APPLI | CANT, ATTORNEY, OF | AGE | NT |
| Firm | | | | | | |
| <i>or</i> Individual name | Heidi M. Berven | | | | | |
| Signature | 1 1/2 | / | | | | |
| Date | 11/19/0 |)3 | | | | |
| | | CE | RTIFIC | ATE OF MAILING | | |
| I hereby certify the | at this correspondence | is heir | na denosit | ed with the United States I | Postal S | Service as first class mail in an |

Typed or printed name Beth N. Gaines

Signature

Date

11/19/03

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

11/19/03

envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

PTO/SB/17 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

I:

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

eCthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

for FY 2001

Patent fees are subject to annual revision.

180.00 **TOTAL AMOUNT OF PAYMENT** (\$)

| Compl te if Known | | | | | | |
|----------------------|----------------------|--|--|--|--|--|
| Application Number | 10/647,358 | | | | | |
| Filing Date | August 25, 2003 | | | | | |
| First Named Inventor | Bisgaier, Charles L. | | | | | |
| Examiner Name | Unknown | | | | | |
| Group Art Unit | 1617 | | | | | |
| Attorney Docket No. | 5790-C1-HMB | | | | | |

| The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to: Deposit Account Number Deposit Account Name Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 Applicant claims small entity status. See 37 CFR 1.27 Payment Enclosed: | Fee | DDIT Larg Entit Fee (\$) 130 | e Fee Code 205 | Sma Entir | ill ty Fee I | Description | | Eas Daid |
|---|---------------------|---|-------------------------|---------------------|---|--|---|---------------|
| Deposit Account Number Deposit Account Name Warner-Lambert Company, LLC Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 Applicant claims small entity status. See 37 CFR 1.27 | 105 127 | Entite Fee (\$) | Fee Code 205 | Enti Fee (\$) | ty Fee I | Description | | Fac Daid |
| Deposit Account Name Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 Applicant claims small entity status. See 37 CFR 1.27 | 105 127 | Fee e (\$) 130 | Fee Code 205 | Fee (\$) | Fee I | Description | | Con Daid |
| Account Name Warner-Lambert Company, LLC Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 Applicant claims small entity status. See 37 CFR 1.27 | 105 127 | 130 | 205 | | Court and Jaka 4 | | JI. | Fee Paid |
| Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 Applicant claims small entity status. See 37 CFR 1.27 | 1 | 50 | 227 | | Surcharge - late i | îling fee or oa | ith | |
| Applicant claims small entity status. See 37 CFR 1.27 | 139 | | 227 | 25 | Surcharge - late p | provisional filir | ng fee or | |
| | | 130 | 139 | 130 | Non-English spec | ification | | |
| 2. I Payment Enclosed: | 147 | 2,520 | 147 | 2,520 | For filing a reque | st for ex parte | reexamination | |
| Check Credit card Money Chor | 112 | 920* | 112 | 920* | Requesting public Examiner action | cation of SIR p | orior to | |
| FEE CALCULATION | 113 | 1,840° | 113 | 1,840 | * Requesting public Examiner action | cation of SIR a | after | |
| 1. BASIC FILING FEE | 115 | 110 | 215 | 55 | Extension for rep | ly within first i | month | |
| Large Entity Small Entity | 116 | 390 | 216 | 195 | Extension for repl | ly within seco | nd month | |
| Fee Fee Fee Fee Description | 117 | 890 | 217 | 445 | Extension for repl | ly within third | month | |
| Code (\$) Code (\$) Fee Paid 101 710 201 355 Utility filing fee | 118 | 1,390 | 218 | 695 | Extension for repl | ly within fourti | n month | <u> </u> |
| 106 320 206 160 Design filling fee | 128 | 1,890 | 228 9 | 945 | Extension for repl | ly within fifth n | nonth | |
| 107 490 207 245 Plant filing fee | 119 | 310 | 219 | 155 | Notice of Appeal | | | |
| 108 710 208 355 Reissue filing fee | 120 | 310 | 220 | 155 | Filing a brief in su | pport of an ap | peal | |
| 114 150 214 75 Provisional filing fee | 121 | 270 | 221 | 135 | Request for oral h | nearing | | |
| | 138 | 1,510 | 138 1 | ,510 | Petition to institute | e a public use | proceeding | |
| SUBTOTAL (1) (\$) 0.00 | 140 | 110 | 240 | 55 | Petition to revive | - unavoidable | | |
| 2. EXTRA CLAIM FEES | 141 | 1,240 | 241 | 620 | Petition to revive | - unintentional | , | |
| Fee from Extra Claims below Fee Paid | 142 | 1,240 | 242 | 620 | Utility issue fee (o | r reissue) | | |
| Total Claims -20** = X 18.00 = 0.00 | 143 | 440 | 243 | 220 | Design issue fee | | | |
| Independent - 3** = X 80.00 = 0.00 |] 144 | 600 | 244 | 300 | Plant issue fee | | | |
| Multiple Dependent 0.00 = 0.00 | 122 | 130 | 122 | 130 | Petitions to the C | ommissioner | | |
| | 123 | 50 | 123 | 50 | Processing fee ur | nder 37 CFR 1 | I.17(q) | |
| Large Entity Small Entity Fee Fee Fee Fee Description | 126 | 180 | 126 | 180 | Submission of Infe | ormation Disc | losure Stmt | 180.00 |
| Fee Fee Fee Fee Fee Description Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20 | 581 | 40 | 581 | 40 | Recording each p | | | |
| 102 80 202 40 Independent claims in excess of 3 | 146 | 710 | 246 | 355 | Filing a submissio | n after final re | · · · · · · · · · · · · · · · · · · · | |
| 104 270 204 135 Multiple dependent claim, if not paid | 440 | 740 | 240 | 255 | (37 CFR § 1.129) | | | |
| 109 80 209 40 ** Reissue independent claims over original patent | 149 | 710 | 249 | 355 | For each addition examined (37 CF | | | |
| 110 18 210 9 ** Reissue claims in excess of 20 | 179 | 710 | 279 | 355 | Request for Conti | nued Examina | ation (RCE) | |
| and over original patent | 169 | 900 | 169 | 900 | Request for expe | | ition | _ 7 |
| |] | | :6. | | of a design appli | cation | } | |
| 1/e\ | Other | 166 (2) | pecny) | | | | | |
| SUBTOTAL (2) (\$) 0.00 | | | y Basic | Filing | Fee Paid S | UBTOTAL | (3) (\$) | 180.00 |
| SUBTOTAL (2) (\$) 0.00 | *Redu | uceu by | | | | | | |
| **or number previously paid, if greater; For Reissues, see above | | | | | | Complete (if | applicable) | |
| **or number previously paid, if greater; For Reissues, see above | 1 | Registra Attorney | | | 8,951 | Complete (if | epplicable) (734) 622- | 5218 |
| **or number previously paid, if greater; For Reissues, see above | 1 | Registra | | | 8,951 | | | |
| **or number previously paid, if greater; For Reissues, see above SUBMITTED BY Name (Print/Type) Heidi M. Baryen | Į, | Registra Attorney | /Agent | 4 | | Telephone Date | (734) 622- 11/19/2003 | |
| **or number previously paid, if greater; For Reissues, see above SUBMITTED BY Name (Printl Type) Heidi M. Baryen Signature | nay bec | Registra Attorney | <i>dAgent</i> public | c. Cre | dit card inform | Telephone Date ation shoul | (734) 622- 11/19/2003 d not | |
| **or number previously paid, if greater; For Reissues, see above SUBMITTED BY Name (Printl Type) Heidi M. Beryen Signature WARNING: Information on this form n | may bed dit card | Registra Attorney come information | public matic | c. Cre | edit card inform d authorization ding upon the need | Telephone Date ation shoul on PTO-203 ds of the indivi | (734) 622- 11/19/2003 d not 38. idual case. Any | y comments on |

| SUBMITTED BY | | | | Complete (if applicable) | | |
|-------------------|------------------|-----------------------------------|--------|--------------------------|----------------|--|
| Name (Print/Type) | Heidi, M. Beryen | Registration No. (Attorney/Agent) | 48,951 | Telephone | (734) 622-5218 | |
| Signature | | | | Date | 11/19/2003 | |

USSN: 10/647,358 Fil d on: 8-25-03 Docket No.: 5790-C1-HMB Application Number Number (Optional) 09/485242 5790-01-CA PINFORMATION DISCLOSURE CITATION Applicant(s) **BISGAIER, CHARLES LARRY** (Use several sheets if necessary) Filing Date Group Art Unit **FEBRUARY 7, 2000 U.S. PATENT DOCUMENTS** FILING DATE EXAMINER CLASS SUBCLASS NAME DATE REF DOCUMENT NUMBER IF APPROPRIATE **INITIAL** 514 557 LEE, ET AL. 5,589,611 02/06/1996 514 547 07/15/1997 **BISGAIER** 5,648,387 FOREIGN PATENT DOCUMENTS Translation SUBCLASS CLASS DOCUMENT NUMBER DATE COUNTRY REF YES NO wo 07/22/1993 93/13801 J 10/23/1996 EP 0 738 510 A2 97/14403 04/24/1997 wo 09/02/1993 wo 93/16690

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Glueck, et al, The American Journal of Card., "Gemfibrozil-Lovastatin Therapy for Primary Hyperlipoproteinemias" 1992, Vol. 70:1 PP. 1-9.

Haag, et al., Cellular Singalling, "Lovastatin Inhibits Receptors-Stimulated Ca2+-Influx in Retinoic Acid Differentiated U937 and HL-60 Cells" 1994, Vol. 6:7; PP. 735-742

Ramires, et al., Intern'l Journal of Card., "Effect of Gemfibrozil Versus Lovastatin on Increased Serum Lipoprotein(a) levels of patients with hypercholesterolemia", 1995, vol. 48:2; PP. 115-120.

Dimitroulakos, et al., Nature Medicine, "HMG-CoA Reductase Mediates the Biological Effects of Retinoic Acid On Human Neuroblastoma Cells: Lovastatin Specifically Targets P-Glycoprotein-Expressing Cells" 1996, 2:3 PP. 326-333

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USSN: 10/647,358 Fil d on: 8-25-03 Docket Number (Optional) Docket No.: 5790-C1-HMB Application Number 5790-01-CA 09/485242 **TPINFORMATION DISCLOSURE CITATION** Applicant(s) **BISGAIER, CHARLES LARRY** (Use several sheets if necessary) Filing Date Group Art Unit NOV 2 4 2003 **FEBRUARY 7, 2000 U.S. PATENT DOCUMENTS** EXAMPLER INITIAL RÉF FILING DATE DOCUMENT NUMBER DATE NAME CLASS SUBCLASS IF APPROPRIATE . : FOREIGN PATENT DOCUMENTS Translation REF DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Ramharack, et al., Biochemical and Biophysical Research Comm., "Retinoids Inhibt Primary cynomolgus Monkey Hepatocyte Lipoprotein(a) Levels" 1997, Vol. 238:1, PP. 48-52 Krause, et al., Expert Opinion on Investigational Drugs, "Emerging Therapies in Atherosclerosis", 1995, Vol. 4:5, PP. 353-387 PCT International Serach Report, PCT/US98/23480 EXAMINER **DATE CONSIDERED** EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Form PTO-A820

| Please type a plus sign (+) inside this box -> + | Please type a | plus sign | (+) inside | this box | -> | + |
|--|---------------|-----------|------------|----------|----|---|
|--|---------------|-----------|------------|----------|----|---|

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

NOV 2 4 2003 INFO

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| Sheet | 1 | of | |
|-------|-----|----|--|
| | i e | | |

| Complete if Known | | | | | | |
|------------------------|---------------------|--|--|--|--|--|
| Application Number | 10/647,358 | | | | | |
| Filing Date | August 5, 2003 | | | | | |
| First Named Inventor | Charles L. Bisgaier | | | | | |
| Group Art Unit | Not Yet Assigned | | | | | |
| Examiner Name | Not Yet Assigned | | | | | |
| Attorney Docket Number | 5790-C1 | | | | | |

| | | | | U.S. PATENT DOCU | JMENTS | |
|-----------------------|--------------|----------------|---|---|--|--|
| Examiner Initials* | xaminer Cite | | t Document Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | v . | | | | |
| | | | | | | |
| | | **** | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | 11 | | | |
| | | | | | | |
| | | | | | | |
| | | | 1 | | | |
| | - | | | | | |
| | | ·-········· | | | | |
| | | | - | | 1 | |
| | | | - | | + | |
| | | | | | | |
| | | | | | | |
| | | | - | | | |

| | | | | | FORE | IGN PATENT DOCUMENT | rs | | |
|-----------|--|----------|-----------------------------|------------------------------|--|---------------------------------------|------------------------|--|----------|
| Examiner | | | Fo | reign Patent Do | 0.15 | Name of Patentee or | Date of Publication of | Pages, Columns, Lines, Where Relevant | |
| Initials* | | | Applicant of Cited Document | Cited Document MM-DD-YYYY | Passages or Relevant Figures Appear | Тв | | | |
| | | | | | | | | | |
| | | | | | | | | | \vdash |
| | | _ | - | | \longrightarrow | | | | |
| <u> </u> | | | + | | | | | | 1- |
| | | | | • | | | | | |
| | | | | | | | | | |
| | | <u> </u> | ↓ | | | · · · · · · · · · · · · · · · · · · · | | | |
| | | \vdash | ╁ | | | | | | - |

| | | |
|-----------|------------|--|
| Examiner | Date | |
| Signature | Considered | |

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Please | type a | plus sign | (+) | inside | this | box | → | - |
|--------|---|-----------|-----|--------|------|-----|----------|-----|
| | .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | P 0.5 | ٠, | | | | _ | , — |

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Compl t if Known **Application Number** 10/647,358 Filing Date August 5, 2003 First Named Inventor Charles L. Bisgaier Not Yet Assigned Group Art Unit Not Yet Assigned **Examiner Name** Attorney Docket Number 5790-C1

(use as many sheets as necessary) of Sheet

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | |
|---|---|--|
| Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² |
| | Bellosta, et al., Fluvastatin inhibition of MMP-9 activity secreted by macrophages', Atherosclerosis, Vol. 134:1-2, pg. 228 (1997) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | Cite No.1 | Cite No.1 item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Bellosta, et al., Fluvastatin inhibition of MMP-9 activity secreted by macrophages', Atherosclerosis, Vol. |

considered. Include copy of this form with next communication to applicant.

Burden Hour Statement; This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Date

Examiner

Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.